# NCT01140373 (NCT01140373)

> Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

No report yet. It can be ordered.

- Drugs tested: cyclophosphamide
- Indication: castrate metastatic prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01140373
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Memorial Sloan Kettering Cancer Center
- Conditions: Prostate Cancer
- Interventions: engineered autologous T cells; cyclophosphamide
- Enrollment: 13
- Primary outcome: The safety and tolerability of immunotherapy

## Indexed commentary on NCT01140373 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct01140373